Trade Names: | |
Synonyms: | |
Status: | Approved (1989) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | N04BD01 |
UNII: | 2K1V7GP655 |
InChI Key | MEZLKOACVSPNER-GFCCVEGCSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C13H17N |
Molecular Weight | 187.29 |
AlogP | 2.18 |
Hydrogen Bond Acceptor | 1.0 |
Hydrogen Bond Donor | 0.0 |
Number of Rotational Bond | 4.0 |
Polar Surface Area | 3.24 |
Molecular species | BASE |
Aromatic Rings | 1.0 |
Heavy Atoms | 14.0 |
Action | Mechanism of Action | Reference |
---|---|---|
INHIBITOR | Monoamine oxidase B inhibitor | FDA |
Primary Target | |
---|---|
Monoamine oxidase B |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Cytochrome P450
Cytochrome P450 family 2
Cytochrome P450 family 2B
Cytochrome P450 2B1
|
- | - | - | 1050 | - | |
Enzyme
Oxidoreductase
|
- | 0-19600 | 59 | 3-5680 | 4-98 | |
Unclassified protein
|
- | 270 | - | - | - |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Parkinson Disease | 4 | D010300 | ClinicalTrials |
Cocaine-Related Disorders | 3 | D019970 | ClinicalTrials |
Depressive Disorder | 3 | D003866 | ClinicalTrials |
Borderline Personality Disorder | 3 | D001883 | ClinicalTrials |
Prostatic Neoplasms | 2 | D011471 | ClinicalTrials |
Tobacco Use Disorder | 2 | D014029 | ClinicalTrials |
Amphetamine-Related Disorders | 1 | D019969 | ClinicalTrials |
Schizophrenia | 0 | D012559 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 14611-51-9 |
ChEBI | 9086 |
ChEMBL | CHEMBL972 |
DrugBank | DB01037 |
DrugCentral | 2429 |
EPA CompTox | DTXSID6023575 |
FDA SRS | 2K1V7GP655 |
Guide to Pharmacology | 6639 |
KEGG | C07245 |
PharmGKB | PA451316 |
PubChem | 26757 |
SureChEMBL | SCHEMBL22232 |
ZINC | ZINC000019632633 |